Radiation Oncology

Non-small cell lung cancer

Questions discussed in this category

How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?

Would you consider omitting local therapy?

2 Answers available

Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?

One particular circumstance involved detecting a ROS1 fusion upon the metastatic recurrence. Is this pneumonitis risk seen with osimertinib alon...

2 Answers available

How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?

With low #s of patients on the durvalumab PACIFIC trial with EGFR mutated disease, and LAURA trial design of osimertinib until progression, should we ...

3 Answers available

Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?

6 Answers available

For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?

2 Answers available

In oligometastatic NSCLC with a solitary brain metastasis and lung primary amenable to SBRT, how would you sequence first-line systemic therapy versus local therapy to the lung after treatment of the CNS metastasis?

5 Answers available

How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?

Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?

1 Answer available

How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?

Would you offer chemotherapy after radiation is completed?

3 Answers available

Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?

NCCN states that all operable NSCLC patients should be evaluated for pre-op therapy with strong consideration of nivolumab + chemotherapy for those wi...

2 Answers available

How do you treat Stage IIIC T4N3 NSCLC?

Some consider T4N3 Stage IIIC to be a borderline case. None of these patients were included in either PACIFIC or KEYNOTE-024 for example. Would y...

4 Answers available

Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?

E.g. higher central hotspot in solid lesions? Any data on differences in toxicity?

1 Answer available

How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?

1 Answer available

How does the presence of interstitial lung disease affect your decision to offer SBRT for early stage NSCLC?

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

6 Answers available

What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?

2 Answers available

Is there increased risk with lung SBRT in a patient who has a mild asymptomatic pneumothorax in the field after CT-guided needle biopsy?

2 Answers available

Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

If so, when and to what extent?

2 Answers available

Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?

2 Answers available

Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?

Can you explain the expansion cohorts into larger trials and the current amendments to the the protocol?

1 Answer available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

2 Answers available

Do you consider NSCLC with multistation N2 involvement appropriate for treatment with neoadjuvant chemoimmunotherapy followed by surgery?

6 Answers available

In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?

1 Answer available

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

4 Answers available

How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Does the site of treatment factor into your decision?

2 Answers available

Which patients with primary, early-stage NSCLC would you utilize immunotherapy in conjunction with SBRT?

This post refers to the recently published RCT by Chang et al., PMID 37478883 investigating lung SBRT with vs. without 4 months of nivolumab for early...

1 Answer available

How are you approaching patients with early-stage NSCLC who progress on neoadjuvant chemo-immunotherapy and are no longer surgical candidates?

5 Answers available

Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?

1 Answer available

When contouring locally advanced NSCLC, how do you define your ITV if your iGTV overlaps with an OAR?

E.g. esophagus? If you crop the esophagus out of the ITV, then your ITV would not fully encompass the iGTV.

4 Answers available

How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?

The left breast cancer is an ER-negative, PR-negative, HER2-negative cT2N0 invasive ductal carcinoma, while the left lung primary is a cT2N1 squamous ...

5 Answers available

How would you treat an endobronchial NSCLC abutting a hiatal hernia in a patient who is medically inoperable?

2 Answers available

When planning concurrent chemoradiation for locally advanced NSCLC, do you consider prescribing primary tumor disease to a lower isodose line, such as 75%, if OAR constraints for standard prescribing are met?

3 Answers available

Would you offer definitive CRT for stage III(N3) NSCLC treated with neoadjuvant immunotherapy who had a complete radiographic response?

If so, what dose of radiation dose would you use?

2 Answers available

Is there ever a role for adjuvant chemotherapy and/or immunotherapy for early stage, N0 non-small cell lung cancer treated with SBRT alone?

5 Answers available

What are your top takeaways in Thoracic Cancers from ASCO 2023?

5 Answers available

When would you include treatment of the entire staple line for an NSCLC staple line recurrence?

Would you consider treating with conventional fractionation to the entire staple line with a boost to the gross disease?

1 Answer available

How do you define an adequate EBUS when staging NSCLC?

Is there a minimum standard for which stations to sample? Does lymph node size affect your recommendations?

3 Answers available

What dose constraints do you use for 60 Gy in 15-20 fraction lung treatments that are adjacent to the hilum?

3 Answers available

What dose constraint do you use for the proximal bronchial tree for when treating NSCLC to 60 Gy/8 fx?

I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...

2 Answers available

Do you ever start immunotherapy along with WBRT in patients with PDL1 >50% metastatic NSCLC with significant visceral tumor burden in addition to symptomatic brain mets?

4 Answers available

How do you modify your dose constraints when giving lung SBRT to a new lesion in a patient previously treated with lung SBRT?

How does your approach change for same lung but now a different lobe v. different lung? How do you adjust your constraints?

1 Answer available

Do you ever consider small vessel doses when determining your dose for SBRT?

For example, would you modify your SBRT dose next to the azygous vein? While we talk frequently about OAR constraints for the great vessels, it seems ...

1 Answer available

Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

3 Answers available

Do you do recommend further mediastinal staging for patients with SCLC or inoperable NSCLC with N1 disease on PET?

If a patient clearly has N1 disease with high SUV on PET, do you routinely recommend EBUS or mediastinoscopy to evaluate for N2 disease?

1 Answer available

Should IMPower010 results be extrapolated to superior sulcus tumors treated with chemoradiation and surgery?

1 Answer available

Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

2 Answers available

Are there clinical features that would lead you to consider combining SBRT + immunotherapy in a high risk early stage NSCLC?

1 Answer available

How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

1 Answer available

Do you have a maximum size cutoff for lung SBRT in central NSCLC?

E.g. for a 7cm central NSCLC, would you offer 8 fx SBRT or ChemoRT? Patient is not a surgical candidate.

6 Answers available

How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?

5 Answers available

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?

Would you consider SBRT and continue osimertinib?

2 Answers available

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

2 Answers available

Should lung SBRT fractions be delivered on consecutive days, every other day, or perhaps an even more prolonged schedule?

Does tumor location play a role (central vs peripheral) in making the decision? The question stems from an oral presentation at ASTRO 2014 inves...

7 Answers available

Do patients with Stage III unresectable NSCLC with lepidic features require a different approach to chemo-radiation?

Would your choice of concurrent chemotherapy be impacted by this histologic finding?

0 Answers available

Do you offer consolidative thoracic radiation for oligometastatic NSCLC following upfront immunotherapy?

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

2 Answers available

Would you rather start radiation for Stage III NSCLC in the middle of a chemotherapy cycle or wait for the 2nd cycle if it could not be started on cycle 1 day 1?

1 Answer available

How long do you continue surveillance imaging for NSCLC after definitive treatment?

NCCN recommends annual CT surveillance indefinitely after year 5, but I’m curious how many physicians continue and for how long?

3 Answers available

Would you deliver SRS/XRT for isolated asymptomatic CNS metastasis before start of immunotherapy for stage IV lung cancer (negative for driver mutation) with high positive PDL1?

1 Answer available

Do you consider additional chemotherapy or durvalumab after definitive concurrent chemo/RT for Stage II NSCLC for patients who are not surgical candidates?

Would PDL-1 status impact your decision?

3 Answers available

How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

1 Answer available

Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.Antonia et al., PMID 28885881...

3 Answers available

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

CT or PET? If so, how often?

3 Answers available

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

2 Answers available

For patients with inoperable stage III NSCLC who are unable to receive or refuse definitive chemoradiation, how do you decide among radiation alone, pembrolizumab alone, or radiation followed by either pembrolizumab or durvalumab?

5 Answers available

How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?

Do you feel it is important to start durvalumab within 14 days of completing cCRT? What real life challenges do you face in doing so and wh...

1 Answer available

What are the clear criteria for unresectability in locally advanced NSCLC patients, other than medical or anatomic?

Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...

1 Answer available

Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?

3 Answers available

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?

1 Answer available

Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?

If so, how would you modify this regimen?

1 Answer available

If you are treating a patient with palliative radiation for hemoptysis do you require chemotherapy to be held?

If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?

4 Answers available

For stage III NSCLC treated with definitive intent chemoRT, how do you decide to proceed with surgery vs consolidation immunotherapy?

1 Answer available

Do you ever consider a dose constraint to the spleen when treating lung tumors with stereotactic radiotherapy?

I am treating a left lower lobe NSCLC and my PTV is so close to the spleen that a small portion of the spleen is getting significant dose. I can...

3 Answers available

How do you manage a patient who presents with a tracheoesophageal fistula from a lung or esophageal primary that is non-metastatic?

As a for instance, a centrally located primary tumor with mediastinal adenopathy that results in a TE fistula? Currently we would recommend esophagea...

4 Answers available

Would you deliver SBRT to the adrenal gland if a patient has already undergone contralateral adrenalectomy for oligometastatic NSCLC?

What would you anticipate with regard to potential adrenal toxicity when the patient has only 1 functioning adrenal gland? There are no other sites of...

3 Answers available

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

1 Answer available

How would you approach treatment in patients with stage III non small cell lung cancer invading the atrium of the heart?

1 Answer available

Do you recommend elective mediastinal nodal irradiation for an inoperable NSCLC patient with N1 disease who is unable to undergo mediastinal staging?

Does the T stage or location of malignancy affect your decision?

1 Answer available

How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...

1 Answer available

How important is a severely diminished diffusion capacity in determining whether to offer a lung cancer patient radiotherapy?

Does it factor into your decision making in the setting of restricted spirometry and normal lung volumes? Does this differ for SBRT v. chemoRT?

1 Answer available

Should radiotherapy be utilized in stage IVA NSCLC with a malignant pericardial effusion?

If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...

1 Answer available

Would you include any elective nodal stations for cases of T3/T4 node-negative NSCLC staged by PET/CT in which a patient cannot undergo nodal sampling?

Would your answer differ based on whether the patient is receiving concurrent chemotherapy? Are there other factors that would influence this decision...

1 Answer available

For oligometastatic NSCLC that would be otherwise considered stage 3, would you consider consolidative immunotherapy with durvalumab after definitive treatment for both the primary and oligometastatic site?

2 Answers available

When do you choose motion management over free-breathing techniques for lung SBRT?

Do you prefer breath-hold techniques (ABC, DIBH) or abdominal compression regardless of tumor motion? Or do you use a general threshold number of cc's...

1 Answer available

What lung constraint do you use when delivering SBRT for local failure of early stage NSCLC following surgery?

Does this vary based on whether the patient had a lobectomy v. wedge resection?

1 Answer available

Would you offer immunotherapy after chemoradiotherapy for Stage III lung cancer given results of PACIFIC Trial?

If so how would you select patients (ie. PS, histology, PD-L1 expression level)?

2 Answers available

What potential risks of SBRT do you counsel patients on when treating early stage lung cancer with an underlying chronic lung infection?

In a patient with a cavitated lesion with underlying chronic infection (identified as cocci) and SqCC, are there additional risks to SBRT? Should spec...

1 Answer available

How do you manage a stage I LLL medically inoperable lung cancer in close proximity to the stomach?

In patients with aberrant anatomy due to previous surgery with lung PTV overlapping the stomach, how much would you dose de-escalate? Even conventiona...

2 Answers available

Do you use a chest wall constraint when treating large lung cancers with 8 or 10 fraction SBRT?

If so, what constraint is most clinically relevant? The EORTC LungTech trial (60Gy/8 fractions) does not specify a chest wall constraint. I have...

3 Answers available

Do you ever recommend PORT or chemoRT rather than chemotherapy alone for NSCLC with adverse features other than positive margins or N2 disease?

For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...

2 Answers available

Is there concern for hemorrhage after SBRT to a lung metastasis that directly involves a branch of the pulmonary artery?

What dose and fractionation would you consider if surgery is not an option?

1 Answer available

How do you counsel patients in regards to the options and risks for salvage lobectomy/wedge after SBRT?

Do you discuss this at the first consultation? Is there strong evidence to suggest that risks are significantly increased compared to upfront lobectom...

1 Answer available

What is your preferred first line approach to patients with good PS stage IV non-squamous NSCLC that is EGFR/ROS1/ALK/BRAF WT and PDL-1 < 1%?

Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?

2 Answers available

Is surgery preferable over SBRT for peripheral NSCLC invading into ribs?

Is local control worse for SBRT when the tumor is invading into the bone (rib)?

4 Answers available

How would you approach treatment for a patient with locally advanced NSCLC and systemic scleroderma if chemoradiation is their only curative option?

1 Answer available

What factors do you use to decide between phase based vs. amplitude based gating for lung SBRT?

1 Answer available

How do you fractionate SBRT for NSCLC abutting the chest wall or in which the PTV encompasses part of the chest wall?

1 Answer available

Does proximity to or involvement of the aorta effect the dose and fractionation you use for an early stage NSCLC?

For example, a NSCLC of the LLL abutting and potentially involving the adventitia of the descending aorta?

1 Answer available

How does your management of locally advanced NSCLC change in a patient with a previous contralateral pneumonectomy?

For a patient with a new contralateral primary or recurrence and previous pneumonectomy, what lung constraints do you prioritize (ex mean lung dose, V...

1 Answer available

How do you decide on the sequence of systemic and local therapy for patients with oligometastatic NSCLC?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

1 Answer available

When do you recommend induction chemotherapy prior to concurrent chemoradiotherapy for locally advanced NSCLC?

If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...

2 Answers available

Do you recommend concurrent or sequential radiation and chemotherapy for margin-positive, node negative NSCLC?

What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?

2 Answers available

Would you recommend a cycle of chemotherapy prior to concurrent chemoradiation for a Stage III NSCLC patient who needs to start treatment sooner than allowed by the IMRT planning process?

Or would you rather treat with 3D-CRT in order to initiate chemoRT concurrently?

1 Answer available

How do you approach a peripheral, T1 lung cancer with a positive mediastinal node by EBUS?

Is there a role for SBRT to the primary site? Is it required to treat the ipsilateral hilum if no adenopathy was seen on EBUS or PET?

2 Answers available

What dose constraint, if any, do you use for the diaphragm when treating liver or lung tumors with SBRT?

Have you ever seen toxicity related to diaphragm dose with conventional fractionation?

4 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-10-20

Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Cancer, 1998 Mar 15

Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience.

International journal of radiation oncology, biology, physics, 2012-11-01

Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.

JAMA, 2010-03-17

Stereotactic body radiation therapy for inoperable early stage lung cancer.

International journal of radiation oncology, biology, physics, 2017-03-15

Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.

International journal of radiation oncology, biology, physics, 2015-11-15

A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Radiother Oncol, 2013 Aug

Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-10

Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy.

International journal of radiation oncology, biology, physics, 2016-12-01

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Practical radiation oncology, 2018

Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-09-01

Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-01

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Medical and pediatric oncology, 1990

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986-01

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2015-10-22

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Lancet (London, England), 2017-01-21

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

The Lancet. Oncology, 2016-11

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2009-04-01

Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason.

J. Clin. Oncol.,

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Clinical lung cancer, 2016-11

Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion.

International journal of radiation oncology, biology, physics, 2006-07-01

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.

International journal of radiation oncology, biology, physics, 2007-10-01

Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Radiat Oncol, 2015 Apr 26

Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age.

Clin Lung Cancer, 2017 Jul 10

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).

J Thorac Oncol,

Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.

Clinical lung cancer, 2018-07

Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).

Journal of vascular and interventional radiology : JVIR, 2021 Mar 31

Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

International journal of radiation oncology, biology, physics, 2007-02-01

Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2012-05-01

Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes.

International journal of radiation oncology, biology, physics, 2012-02-01

Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).

International journal of radiation oncology, biology, physics, 2010-03-01

Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.

Journal of radiosurgery and SBRT, 2011

Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation.

The Lancet. Oncology, 2017-07

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

International journal of radiation oncology, biology, physics, 2017-06-01

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

JAMA oncology, 2018-01-11

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-08

A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non-Small-Cell Lung Cancer.

Clinical lung cancer, 2015-11

Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.

Am. J. Clin. Oncol., 2007-06-01

A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Medicine (Baltimore),

Ratio of lymph node to primary tumor SUVmax multiplied by maximal tumor diameter on positron emission tomography/integrated computed tomography may be a predictor of mediastinal lymph node malignancy in lung cancer.

Eur Radiol, 2016 Mar 04

The diagnostic ability of F-FDG PET/CT for mediastinal lymph node staging using F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer.

Medical physics, 2011-11

The correlation of tissue motion within the lung: implications on fiducial based treatments.

Clin Lung Cancer, 2017 Mar

Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.

Clin Lung Cancer, 2018 Apr 18

SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial.

Int. J. Radiat. Oncol. Biol. Phys., 2010-06-01

Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.

Thorac Cancer, 2017 Apr 24

Relationship between endobronchial ultrasound-guided (EBUS)-transbronchial needle aspiration utility and computed tomography staging, node size at EBUS, and positron emission tomography scan node standard uptake values: A retrospective analysis.

International journal of radiation oncology, biology, physics, 2013-03-01

Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity.

Respir. Res., 2018 Apr 24

Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer.

International journal of radiation oncology, biology, physics, 2011-10-01

Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer.

International journal of radiation oncology, biology, physics, 2012-06-01

Local failure in resected N1 lung cancer: implications for adjuvant therapy.

Int. J. Radiat. Oncol. Biol. Phys., 2008 Jan 30

Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.

Thorac Surg Clin,

Management of Malignant Tracheoesophageal Fistula.

International journal of radiation oncology, biology, physics, 2013-04-01

Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

International journal of radiation oncology, biology, physics, 2014-04-01

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

J Natl Cancer Inst, 2014 Aug

Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

Practical radiation oncology, 2016

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.

International journal of radiation oncology, biology, physics, 2015-09-01

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

J Thorac Oncol, 2016-07-01

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

N. Engl. J. Med.,

Radiation-induced splenic atrophy in patients with Hodgkin's disease and non-Hodgkin's lymphomas.

PLoS ONE, 2015 Nov 24

Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.

Lancet (London, England), 2009-08-01

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

J. Clin. Oncol., 2015 Nov 02

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

JAMA oncology, 2019-07-01

Future Oncol, 2019 Apr 25

Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.

J Clin Oncol, 2023 Jan 31

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Lancet (London, England), 2023 Jul 18

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.

Lancet (London, England), 2023 Jul 18

Safe and effective systemic therapy for early-stage non-small-cell lung cancer.

International journal of radiation oncology, biology, physics, 2018-03-15

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

J Thorac Oncol, 2019 Feb 16

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

The New England journal of medicine, 2011-08-04

Reduced lung-cancer mortality with low-dose computed tomographic screening.

Clin Oncol (R Coll Radiol), 2017 Nov 16

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

Radiother Oncol, 2020 Jul 31

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

International journal of radiation oncology, biology, physics, 2015-06-01

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.

Chest, 2003-11

Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Lung Cancer, 2020 Nov 13

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Neuropathology, 2019 Mar 13

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Respir Investig, 2014 Nov 13

Disease flare after gefitinib discontinuation.

Lancet, 2021 Sep 20

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Radiation oncology (London, England), 2015-02-18

Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.

The Lancet. Oncology, 2015-02

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Eur Respir J, 2005 Aug

Morbidity and mortality in the surgery arm of EORTC 08941 trial.

N Engl J Med, 2023 Jun 28

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018 Apr 16

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

The Lancet. Oncology, 2020 May 07

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

Translational lung cancer research, 2019 Sep

Pathologic response after modern radiotherapy for non-small cell lung cancer.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009 Aug 21

Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.

Cancers, 2021 Sep 26

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.

Clinical lung cancer, 2023 Jul 25

Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era.

ERJ open research, 2020 Feb 17

International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

Clinical Medicine Insights. Oncology, 2023 Feb 14

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

BMC Cancer, 2019 Aug 19

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Chest, 2016-03

Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report.

Chest, 2008 Feb 08

Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.

JAMA, 2010 Nov 24

Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial.

N Engl J Med, 2021 Jun 04

Sotorasib for Lung Cancers with p.G12C Mutation.

Journal of the National Cancer Institute, 2023 Jun 08

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.

J Thorac Oncol, 2021 Apr 03

The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.

JAMA Oncol,

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

The New England journal of medicine, 2023 Jun 03

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J Thorac Oncol, 2023 Feb 23

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

Cancer journal (Sudbury, Mass.), 2020 Nov/Dec

Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 Feb 12

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Journal for immunotherapy of cancer, 2021 Aug

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.

International journal of cancer, 2019 Feb 19

EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.

The Lancet. Respiratory medicine, 2023 May 05

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Lancet (London, England), 2023 Dec 14

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Apr 22

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.

J. Clin. Oncol., 2008-07-20

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

The Annals of thoracic surgery, 2015-02

Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery.

Lancet (London, England), 2010 Mar 24

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

The New England journal of medicine, 2024 Jun 02

Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

The New England journal of medicine, 2018-01-11

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2024 Feb 20

A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20

Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.

Nature medicine, 2023 Nov 13

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

Journal of neurosurgery, 1998-06

Gamma knife radiosurgery for thalamotomy in parkinsonian tremor: a five-year experience.

Pract Radiat Oncol, 2020 Oct 31

VMAT Grid Therapy: A Widely Applicable Planning Approach.

J Immunother Cancer, 2020 Oct

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.

J Immunother Cancer, 2019 Sep 4

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.

Front Cardiovasc Med, 2023

Ventricular tachycardia ablation through radiation therapy (VT-ART) consortium: Concept description of an observational multicentric trial via matched pair analysis.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016 Sep 03

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Journal of immunology (Baltimore, Md. : 1950), 2005 Jun 15

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

International journal of radiation oncology, biology, physics, 2020 May 15

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2022 Nov 24

Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023 Feb 03

Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival.

Frontiers in oncology, 2023 Sep 06

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer.

Signal transduction and targeted therapy, 2021 Nov 22

Circulating tumor cells: biology and clinical significance.

International journal of radiation oncology, biology, physics, 2024 Apr 12

Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET).

The New England journal of medicine, 2023 Oct 23

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2024 May 16

Perioperative Nivolumab in Resectable Lung Cancer.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

The Lancet. Respiratory medicine, 2024 Mar 12

Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial.

The Lancet. Oncology, 2022 Sep 12

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

Front Oncol, 2023

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.

The New England journal of medicine, 2024 Apr 11

Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.

Lancet Oncol, 2021 Dec 15

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.

J Thorac Oncol, 2018 Mar 06

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).

JTO clinical and research reports, 2022 Jun 25

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced -Positive NSCLC.

Radiation Oncology

Non-small cell lung cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology